Ribupatide
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Ribupatide: Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |